Pfizer’s groundbreaking drug, Lorbrena, has demonstrated revolutionary progress in the treatment of advanced non-small cell lung cancer. Recent long-term results from a late-stage trial have showcased the drug’s ability to significantly extend the lifespan of patients while preventing the progression of cancer. With a remarkable data showing that most individuals experienced positive outcomes for over